The global osteoporosis drugs industry was estimated at $7.65 billion in 2018, and is expected to hit $10.47 billion by 2026

11/nov/2020 17:43:44 Automotive Market Research Reports Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Increase in prevalence of osteoporosis, increase in the aging population, and adoption of sedentary lifestyle across the world drive the growth of the global osteoporosis drugs market. However, side effects related to osteoporosis drugs and time-consuming approval processes for drugs hinder the market growth. On the other hand, high potential for growth in developing countries would offer new opportunities in the coming years.

The global osteoporosis drugs industry was estimated at $7.65 billion in 2018, and is expected to hit $10.47 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.

 

 

Based on drug class, the bisphosphonates segment held more than one-third of the total market share in 2018, and is estimated to maintain its largest share in terms of revenue throughout the forecast period. However, the rank ligand inhibitors segment is estimated to witness the highest CAGR of 8.6% from 2019 to 2026. The report also analyzes segments including selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, and others.

The oral segment to maintain the lion’s share during the estimated period-

Based on route of administration, the oral segment held the major share in 2018, garnering nearly three-fifths of the global osteoporosis drugs market, owing to the large number of osteoporosis medications, which are available as oral drugs in the market. Simultaneously, the injectable segment would manifest the CAGR of 4.4% throughout the forecast period, owing to factors such as rise in need for drugs, which exhibit enhanced bioavailability and act rapidly

Key market players-

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Radius Health
  • Merck & Co. Inc.
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

North America to lead the trail till 2026-

Based on region, North America accounted for nearly half of the global osteoporosis drugs market share in 2018, and is projected to rule the roost during the study period. Owing to easy availability of osteoporosis drugs and surge in incidence of osteoporosis. At the same time, the LAMEA region would portray the fastest CAGR of 5.5% by 2026. This is attributed to increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. In addition, the constantly evolving life science industry fuels the growth of the market in the developing economies such as India, China, and Malaysia.

Web: https://www.alliedmarketresearch.com

SOURCE: Allied Market Research

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl